129 related articles for article (PubMed ID: 34185084)
41. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
Dodick DW; Tepper SJ; Friedman DI; Gelfand AA; Kellerman DJ; Schmidt PC
Headache; 2018 Jul; 58(7):986-992. PubMed ID: 29782049
[TBL] [Abstract][Full Text] [Related]
42. Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.
Clark O; Mahjoub A; Osman N; Surmava AM; Jan S; Lagman-Bartolome AM
Neurol Sci; 2022 Jan; 43(1):153-165. PubMed ID: 34698941
[TBL] [Abstract][Full Text] [Related]
43. Long-term efficacy and tolerability of rizatriptan wafers in migraine.
Cady R; Crawford G; Ahrens S; Hairwassers D; Getson A; Visser WH; Lines C;
MedGenMed; 2001 Jun; 3(3):1. PubMed ID: 11549974
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
45. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
Lipton RB; Baygani SK; Tepper SJ; Krege JH; Vasudeva R; Pearlman EM; Hauck PM; Loo LS
J Headache Pain; 2021 Aug; 22(1):101. PubMed ID: 34454420
[TBL] [Abstract][Full Text] [Related]
46. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
[TBL] [Abstract][Full Text] [Related]
47. Temporal analysis of remote electric neuromodulation for the prevention of migraine.
Blumenfeld AM; Rabany L; Ironi A; Stark-Inbar A; Harris D; Halker Singh RB; Harriott AM
Pain Manag; 2023 Aug; 13(8):425-432. PubMed ID: 37615080
[No Abstract] [Full Text] [Related]
48. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
[TBL] [Abstract][Full Text] [Related]
49. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
Winner P; Rothner AD; Saper J; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
[TBL] [Abstract][Full Text] [Related]
50. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
51. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
[TBL] [Abstract][Full Text] [Related]
52. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
53. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
54. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
[TBL] [Abstract][Full Text] [Related]
55. WITHDRAWN: Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2007 Jul; 2001(1):CD003224. PubMed ID: 17636718
[TBL] [Abstract][Full Text] [Related]
56. Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
Winner P; Farkas V; Štillová H; Woodruff B; Liss C; Lillieborg S; Raines S;
Headache; 2016 Jul; 56(7):1107-19. PubMed ID: 27329280
[TBL] [Abstract][Full Text] [Related]
58. Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine.
Nahas SJ; Hindiyeh N; Friedman DI; Elbuluk N; Kellerman DJ; Foreman PK; Schmidt P
J Headache Pain; 2021 May; 22(1):37. PubMed ID: 34001002
[TBL] [Abstract][Full Text] [Related]
59. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
60. DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
CNS Drugs; 2019 Apr; 33(4):375-382. PubMed ID: 30877622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
